Sun Pharma: Sun Pharma resets goals, to focus on quality

Dilip Shanghvi, managing director of Sun Pharmaceuticals, which has faced recent scrutiny from the FDA over issues at its plants, said he is trying to streamline quality-control processes that were overtaken by the merger with Ranbaxy, reported The Economic Times.

• "All of a sudden, [following the merger] we became twice the size of the company," he stated, adding that this "crystallised the need for working towards a system, working towards technology emphasis on improving IT backgrounds, focussing on issues that have affected us and also others in the world in regarding quality."

• Shanghvi said "we require different organisation to manage the increasing complexity of managing our manufacturing sites."

• He added "the emphasis and focus was on common quality rather than country specific or geography specific quality. I think the objective is work towards enhancing our capabilities reaching towards global standard."

• Since the merger, the combined company has standardised its quality metrics across plants on various issues impacting product quality, but Shanghvi acknowledged that some concerns remain.